Advancing Regulatory Adoption of New Approach Methodologies.

Authors

Jeffry Florian, Kimberly Chiu, Rebecca Racz, C Lee Elmore, Shirley K Seo, Ksenia Blinova, Wendy W Wu, Rodney Rouse

Published in

Clinical pharmacology and therapeutics. Sep 18, 2026. Epub Sep 18, 2026.

Abstract

The U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) has a long history advancing new approach methodologies (NAMs). In collaboration with external organizations and other regulatory agencies, FDA supports continued development of NAMs for regulatory use. Within CDER, qualification programs and interdisciplinary review teams provide opportunities for increased regulatory impact of NAMs. CDER also continues to provide regulatory input to NAMs developers and end users to advance regulatory acceptance of NAMs.

PMID:
42757693
Bibliographic data and abstract were imported from PubMed on 18 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.